Eileen M. O’Reilly, MD, discusses the randomized phase II trial of gemcitabine and cisplatin versus gemcitabine and cisplatin and veliparib (ABT-888) in patients with pancreas adenocarcinoma (PDAC) harboring a known germline BRCA or PALB2 mutation, which was presented at the 2020 Gastrointestinal Cancers Symposium.
Both study arms were initially considered to be experimental arms, says O’Reilly. Read more . . .